Sam Fazeli

It's already at the lower end of what some of your colleagues in other companies in China are spending.

So is the company prepared to provide that investment, obviously, that's required?

Or are the net and EBITDA margins sacrosanct, which is always a fight between those two sides, right?

Apologies if I've got my number wrong.

I hope it's the only thing I get wrong this morning.

So, okay, let's talk about some specific products now.

One of my favorite in the Henleus Fosun Pharma world is Serplulimab.

And I learned a lot more about this at the latest WCLC conference, World Conference on Lung Cancer, than before.

The first thing I learned also is that it is the highest ranked product for small cell lung cancer in Europe by ESMO.

And this is completely home developed, if I'm not wrong.

So I'm interested in the story of serplulimab.

It is a PD-1 checkpoint inhibitor.

And I've seen head-to-head data that looks really exciting and interesting.

And of course, you've got this bridging study that you already spoke about in small cell lung cancer in the US.

It's literally going up against the standard of care, which is dyscentric plus chemo.

So I'm interested in the story of this molecule and what your ambitions for it are.

When I searched around, I didn't find too many other indications being tested out.

But just tell us a little bit about this and when we should expect data and what its history is, because it is one of those situations where a molecule was discovered that is better than what's, at least in this indication.

Well, that's a good ambition to have, right?

Yeah.